Cell:新型血检技术或可扩大液体活检的范围

2016-01-21 佚名 生物谷

当细胞死亡后,其并不会消失地无影无踪,相反其会以游离DNA的形式留下一下“指纹”痕迹,而在人类机体中,这些小型的DNA片段就会在血液中被发现;近些年来游离DNA的研究领域应运而生了一种称之为“液体活检”的新技术,该技术可以诊断并且监测某些癌症,鉴别出胎儿机体异常,并且评估移植器官的健康性,进行这些操作仅需要简单的抽血就可以完成,尽管这些检测潜力巨大,但目前其所检测的范围却非常有限。 发表在C

当细胞死亡后,其并不会消失地无影无踪,相反其会以游离DNA的形式留下一下“指纹”痕迹,而在人类机体中,这些小型的DNA片段就会在血液中被发现;近些年来游离DNA的研究领域应运而生了一种称之为“液体活检”的新技术,该技术可以诊断并且监测某些癌症,鉴别出胎儿机体异常,并且评估移植器官的健康性,进行这些操作仅需要简单的抽血就可以完成,尽管这些检测潜力巨大,但目前其所检测的范围却非常有限。

发表在Cell上的一篇报道中,华盛顿大学的科学家就表示他们开发了一种新方法可以克服当前液体活检技术的局限性,从而就以帮助鉴别出哪些类型的细胞可以产生游离DNA;这种方法可以扩大液体活检的检测范围,其依赖于对个体机体中游离DNA的片段谱系进行分析,同时将这种谱系信息同细胞多种死亡生理条件进行对比。

研究者Shendure说道,我们的研究表明,通过观察游离DNA的片段谱或许就可以帮助鉴别出产生游离DNA的特殊组织,而这种方法替代了直接寻找DNA特殊突变的方法;新型检测技术可以对每个DNA片段的末端进行检测,并且找到DNA的热点区域;为了“装入”细胞核,DNA就必须进行卷曲,不断折叠形成紧密的包裹形式,而该过程的关键就是名为核小体的结构,核小体是由DNA和组蛋白组成的染色质基本结构单位,其在整个基因组中以串联形式排列,就好像细绳上的珠子一样,机体中的每个细胞都会以不同方式将DNA紧密压缩,而这些差异性就给每个细胞游离DNA带上了一定的标记。

研究者假设他们可以利用这些“指纹”来追溯游离DNA的来源,而为了完成这项工作,他们首先必须知道DNA的哪些部分缠绕在核小体上的;在细胞死亡期间DNA就会被酶类切割成小片段,而研究者表示,在人类基因组中很有可能存在1300万个核心体的位置。利用癌症患者的血液样本,研究者就发现,不同的癌症类型可以在游离DNA上产生不同的核小体指纹,对于某些癌症患者而言,研究者就可以鉴别出肿瘤的解剖学来源。

大多数的液体活检技术都会寻找机体中不同细胞间的特殊DNA错配,比如存在于肿瘤细胞但不存在于健康细胞的突变等,研究者认为这种新型检测技术的优势就在于其甚至可以对遗传特性相当的两个细胞进行有效区分;目前这种新技术可以对液体活检不能诊断的一系列疾病进行检测,而研究者希望新型检测技术可帮助进行诸如心脏疾病、中风及自身免疫等疾病的诊断。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869291, encodeId=cee41869291b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 25 13:27:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105880, encodeId=c73a1058809f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959547, encodeId=f119195954e00, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Feb 18 17:27:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62180, encodeId=97416218078, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRup3ZySN7pRumibhPI2BoiaQhKq1nNw12XV6fialRdJCf2SibHI6STP24k3xKprg64xq7krHibhHWfTwe/0, createdBy=283f1318137, createdName=上官海棠, createdTime=Sat Jan 30 06:26:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61066, encodeId=22666106671, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:27:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61065, encodeId=dc6a6106562, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:26:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277964, encodeId=783912e79643b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446999, encodeId=eced1446999a7, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869291, encodeId=cee41869291b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 25 13:27:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105880, encodeId=c73a1058809f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959547, encodeId=f119195954e00, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Feb 18 17:27:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62180, encodeId=97416218078, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRup3ZySN7pRumibhPI2BoiaQhKq1nNw12XV6fialRdJCf2SibHI6STP24k3xKprg64xq7krHibhHWfTwe/0, createdBy=283f1318137, createdName=上官海棠, createdTime=Sat Jan 30 06:26:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61066, encodeId=22666106671, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:27:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61065, encodeId=dc6a6106562, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:26:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277964, encodeId=783912e79643b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446999, encodeId=eced1446999a7, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1869291, encodeId=cee41869291b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 25 13:27:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105880, encodeId=c73a1058809f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959547, encodeId=f119195954e00, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Feb 18 17:27:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62180, encodeId=97416218078, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRup3ZySN7pRumibhPI2BoiaQhKq1nNw12XV6fialRdJCf2SibHI6STP24k3xKprg64xq7krHibhHWfTwe/0, createdBy=283f1318137, createdName=上官海棠, createdTime=Sat Jan 30 06:26:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61066, encodeId=22666106671, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:27:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61065, encodeId=dc6a6106562, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:26:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277964, encodeId=783912e79643b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446999, encodeId=eced1446999a7, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-02-18 仁医06
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869291, encodeId=cee41869291b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 25 13:27:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105880, encodeId=c73a1058809f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959547, encodeId=f119195954e00, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Feb 18 17:27:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62180, encodeId=97416218078, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRup3ZySN7pRumibhPI2BoiaQhKq1nNw12XV6fialRdJCf2SibHI6STP24k3xKprg64xq7krHibhHWfTwe/0, createdBy=283f1318137, createdName=上官海棠, createdTime=Sat Jan 30 06:26:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61066, encodeId=22666106671, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:27:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61065, encodeId=dc6a6106562, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:26:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277964, encodeId=783912e79643b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446999, encodeId=eced1446999a7, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-30 上官海棠

    好!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1869291, encodeId=cee41869291b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 25 13:27:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105880, encodeId=c73a1058809f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959547, encodeId=f119195954e00, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Feb 18 17:27:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62180, encodeId=97416218078, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRup3ZySN7pRumibhPI2BoiaQhKq1nNw12XV6fialRdJCf2SibHI6STP24k3xKprg64xq7krHibhHWfTwe/0, createdBy=283f1318137, createdName=上官海棠, createdTime=Sat Jan 30 06:26:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61066, encodeId=22666106671, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:27:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61065, encodeId=dc6a6106562, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:26:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277964, encodeId=783912e79643b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446999, encodeId=eced1446999a7, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-27 李继凯

    文章不错

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1869291, encodeId=cee41869291b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 25 13:27:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105880, encodeId=c73a1058809f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959547, encodeId=f119195954e00, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Feb 18 17:27:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62180, encodeId=97416218078, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRup3ZySN7pRumibhPI2BoiaQhKq1nNw12XV6fialRdJCf2SibHI6STP24k3xKprg64xq7krHibhHWfTwe/0, createdBy=283f1318137, createdName=上官海棠, createdTime=Sat Jan 30 06:26:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61066, encodeId=22666106671, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:27:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61065, encodeId=dc6a6106562, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:26:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277964, encodeId=783912e79643b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446999, encodeId=eced1446999a7, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-27 李继凯

    厉害

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1869291, encodeId=cee41869291b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 25 13:27:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105880, encodeId=c73a1058809f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959547, encodeId=f119195954e00, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Feb 18 17:27:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62180, encodeId=97416218078, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRup3ZySN7pRumibhPI2BoiaQhKq1nNw12XV6fialRdJCf2SibHI6STP24k3xKprg64xq7krHibhHWfTwe/0, createdBy=283f1318137, createdName=上官海棠, createdTime=Sat Jan 30 06:26:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61066, encodeId=22666106671, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:27:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61065, encodeId=dc6a6106562, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:26:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277964, encodeId=783912e79643b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446999, encodeId=eced1446999a7, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-23 smlt2008
  8. [GetPortalCommentsPageByObjectIdResponse(id=1869291, encodeId=cee41869291b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 25 13:27:00 CST 2016, time=2016-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105880, encodeId=c73a1058809f, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:12:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959547, encodeId=f119195954e00, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Feb 18 17:27:00 CST 2016, time=2016-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=62180, encodeId=97416218078, content=好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRup3ZySN7pRumibhPI2BoiaQhKq1nNw12XV6fialRdJCf2SibHI6STP24k3xKprg64xq7krHibhHWfTwe/0, createdBy=283f1318137, createdName=上官海棠, createdTime=Sat Jan 30 06:26:00 CST 2016, time=2016-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61066, encodeId=22666106671, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:27:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61065, encodeId=dc6a6106562, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:26:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277964, encodeId=783912e79643b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446999, encodeId=eced1446999a7, content=<a href='/topic/show?id=549489135c5' target=_blank style='color:#2F92EE;'>#血检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89135, encryptionId=549489135c5, topicName=血检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc1f5300484, createdName=Luyuxie_11, createdTime=Sat Jan 23 08:27:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-23 Luyuxie_11

相关资讯

STM:血液检测可预测乳腺癌药物抵抗

  科学家最近开发出一种具有高灵敏度的血液检测方法,可以确定乳腺癌何时对标准激素治疗法产生抵抗,他们还证明这种检测方法能够指导病人如何进行进一步治疗。   研究人员表示这种方法能够在乳腺癌细胞对芳香酶抑制剂产生抵抗的早期阶段给予病人警告,芳香酶抑制剂是治疗雌激素受体阳性乳腺癌的常用药物。他们发现这种新方法能够检测雌激素受体基因ESR1发生的基因突变,特别是接受了芳

Move Disor:新型血液检测诊断早期帕金森

近日,一篇发表于国际杂志Movement Disorders上的研究论文中,来自西奈山医疗中心(Mount Sinai Medical Center)的研究人员通过研究开发了一种新型血液检测手段,其或许可以准确鉴别出帕金森疾病发病的血液标记或生物标志物;相关研究成果或为开发寻找新型生物标志物的新方法来帮助预测个体是否患帕金森疾病带来一定的帮助。文章中,研究者分析了四组小鼠的血样以此来形成帕金森疾病

Science:一滴血检测病毒感染史

霍华德休斯医学研究所(HHMI)的研究人员开发了一项新的技术,使人们有可能通过一滴血来检测目前和曾经任何已知人类病毒的感染情况。这个方法称为VirScan,是一种有效的测试病毒感染的替代诊断方法。文章发表在最新一期的Science杂志上。VirScan工作原理是筛查血液中存在的针对任何206种已知感染人类的病毒的抗体。我们的免疫系统在检测到病毒首次入侵的时候,会产生病原体特异性抗体,即使病毒感染清

Alzheimer''s & Dementia:老年痴呆可血液检测?

近日研究发现,简单的血液测试可用来检测老年人早期阿尔茨海默病。在血液检测前需要详细的标准化指导指南来指导实践,相关文章已发表在《阿尔茨海默病和痴呆》杂志上。“如果我们使阿尔茨海默氏症的血液测试成为初级保健的必检项目,那么我们必须有指导指南。”Sid O ' bryant博士说,他是北德克萨斯大学保健中心衰老和阿尔茨海默氏症研究所研究中心主任。“高度严格的指导指南将指导研究阿尔茨海默氏症以血液为基础

J Mol Med:新型血液检测手段提前诊断1型糖尿病

近日,发表于国际杂志Journal of Molecular Medicine上的一项研究报告中,来自伦敦帝国理工学院的研究人员通过研究,首次在患早期1型糖尿病患者的机体血液中发现了一种循环的特殊小分子,同时研究者还开发出了一种新型的简单血液检测手段,该技术可以在患者症状并未发生之前就可以对患者机体中的生物标志物进行检测。 研究者Mathieu Latreille说道,如果我们可以鉴别并且早日治

Sci Transl Med:通过血液检测肿瘤基因,可预测肿瘤复发

现代医学面临的挑战之一就是如何得知癌症患者机体的肿瘤何时会复发。一项新的研究显示,可通过“跟踪突变”的血液检测可以发现肿瘤患者体内的复发迹象。ICR和皇家马斯登医院进行的这项研究为改变临床肿瘤监测方式和治疗决策具有十分重要的意义。判断肿瘤是否复发主要是依据血液中是否可以检测到肿瘤基因。它将会产生新的肿瘤细胞并导致机体肿瘤的复发。研究对象为55位乳腺癌早期术后的患者。通过对手术后的肿瘤患者进行血液监